Fwd: Exclusive Interview: Richard Cote, University of Miami, talks CTCs

-------- Original Message --------

Subject:	Exclusive Interview: Richard Cote, University of Miami, talks CTCs
Date:	Tue, 30 Aug 2011 14:31:07 -0400 (EDT)
From:	FierceBiotech Research <editors@fiercebioresearcher.com>
Reply-To:	editors@fiercebioresearcher.com
To:	nbrauchitsch@yahoo.com

This week's FierceBiotech Research is brought to you by Hanson Wade.

3rd World Circulating Tumor Cells Summit Technologies and techniques to practically apply CTCs in the clinic and unleash their full commercial potential 8th - 10th November San Diego www.ctc-summit.com   Download Brochure | Pricing & Discounts | Register Now Dear Colleague, I hope you received my previous email about the 3rd Annual Circulating Tumor Cells Summit, which will be held in San Diego on 8th–10th November.   It is quite simply a meeting that cannot be missed.   Download the brochure now to find out why. While putting together the meeting I spoke with Richard Cote from the University of Miami. He shared his thoughts about the most exciting areas of de velopment in the field; and we spoke about the current work he is doing with CTCs and cancer dissemination. Richard’s insights were so interesting that I thought I’d share them with you. I’ve compiled them in to an exclusive Interview, a snapshot of which is below…     Richard J Cote Professor and Chair, Department of Pathology & Director, Biomedical Nanoscience Institute University of Miami Question: What work still needs to be done to validate the use of CTCs in the clinic?   One of the challenges with validating technologies is that the technologies are evolving so qui ckly. We need to know what are the questions and what we are trying to learn from CTCs, and then ask whether that technology addresses those questions in an actionable way. In some cases there has already been validation of technology. The FDA approved Cell Search is validated for a certain practice in certain types of cancers. One of the challenges is that it’s one thing to say we can now predict whether patients are responding to a certain regimen, but we don’t yet know whether, if we change the regimen, will patients have a response? The evolving nature of the technology and complexity of the technologies themselves is a big challenge.  Question: What potential do CTCs have for oncolog y drug development, and particularly for personalized healthcare? Regarding drug development, we know we can detect CTCs in mouse models. Using this technology in the earlier stages of drug development to ask questions of efficacy would be very interesting, and has the possibility of greatly speeding up early pre-clinical work.. In the later stages, if we had a marker of therapeutic efficacy or failure that would fundamentally change the way we conduct clinical trials, it would speed up clinical development. CTCs can also show us the potential therapeutic targets in this population of cells.  Download the rest of the interview now Richard will be speaking at the Circulating Tumor Cells Summit about methods to easily assess CTCs to monitor disease progression and therapeutic efficacy, leading to high utility value in the clinic. His full interview is availab le to download for free at: www.ctc-summit.com Here, you can also view the full conference agenda, with details of Richard’s presentation, as well as presentations from Amgen, Pfizer, Veridex, Abbott Laboratories, Silicon Biosystems, GlaxoSmithKline and Genentech. < div>Plus, there will be two in-depth workshops, focusing on advanced techniques for the detection, enumeration and characterization of CTCs and streamlining research on CTCs to clinical practice; and interactive debates discussing the practical applications of CTCs in in oncology drug development and how to evaluate and implement emerging technologies.   Download the brochure for a comprehensive overview of the meeting. Register before Friday 20th September and receive up to 300 USD off standard prices. To claim your discount please remember to quote your priority booking code: FB2   To register simply:  Call: +44 (0) 203 1418 700 Email: info@hansonwade.com  Visit: www.ctc-summit.com Or reply to my email and I’ll handle your registration myself.   I look forward to hearing your thoughts and comments about the interview, and to meeting you at the summit in November.   Kind Regards, Jodie   Jodie Paula Cohen Event Director Hanson Wade

Want to reach 40,000+ FierceBiotech Research subscribers with your own message? Contact ryan@fiercemarkets.com or call 202-824-5089.   About this email: In order to receive FierceBiotech Research for free, we ask that you accept an occasional email promotion from our sponsors. We carefully screen each promotion and never sell or give away your personal information. If you do not want to receive these messages, you can unsubscribe entirely from FierceBiotech Research. Click here to unsubscribe. FierceMarkets 1900 L St. NW Suite 400  Washington, DC 20036